BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 16, 2017
View Archived Issues
Replimune doses first cohort in phase I/II study of RP-1
Read More
AstraZeneca presents regulatory and pipeline developments of third quarter 2017
Read More
Numerate receives grant from NIH to develop EZH2 inhibitor-coated orthopedic implants
Read More
Phase I PK data support continued development of COTI-2
Read More
Inozyme Pharma announces series A financing to develop its lead enzyme replacement therapy
Read More
Phase II results for Rottapharm's CR-4056 in knee osteoarthritis pain
Read More
Galapagos's GLPG-1972 well tolerated in healthy volunteers
Read More
Marketing applications for volanesorsen accepted in U.S., E.U. and Canada
Read More
Committee recommends continuation of phase III Atlantis study of Zepsyre
Read More
Zymeworks and Janssen Biotech enter license agreement to develop bispecific antibody therapeutics
Read More
PF-22688 reduces chronic pain induced by cancer in mouse and rat models
Read More
Lilly initiates phase II study of LY-3154207 in Parkinson's disease dementia
Read More
AstraZeneca begins phase I study of AZD-4573 in relapsed or refractory hematological malignancies
Read More
European Commission approves Trelegy Ellipta
Read More
First patient enrolled in Japanese TREASURE study of MultiStem in stroke
Read More
Nitric oxide-releasing chitosan BIOC-51 bactericidal against several pathogens
Read More
TiGenix announces European trade name and INN for Cx-601
Read More
FDA approves Mepsevii for mucopolysaccharidosis type VII
Read More
Samumed patents novel Wnt signaling inhibitors
Read More
Roche, Genentech describe new Janus kinase inhibitors
Read More
Novel vasopressin V1A and V2 receptor antagonists developed at Bayer
Read More
Inception 1 discovers novel NADPH oxidase 4 inhibitors
Read More
Rudong SIMR Biotech presents new GABRA5 inverse agonists
Read More
Sangamo treats first patient with in vivo genome editing therapy SB-913 for MPS II
Read More
Gout candidate URC-102 shows promise in phase II trials
Read More
Acorda updates status of phase III program of tozadenant following cases of agranulocytosis
Read More
GlaxoSmithKline studies GSK-2618960 in primary Sjogren's syndrome
Read More
AbbVie initiates phase I study of ABBV-321 in advanced solid tumors likely to overexpress EGFR
Read More
Atridia studies HTI-1090 for advanced solid tumors in phase I
Read More